Elicera Therapeutics Faces U.S. Patent Setback for iTANK CAR-T Enhancement Platform

Elicera Therapeutics (search)Search term AB faced a significant regulatory setback on September 8, 2025, when the United States Patent and Trademark Office (USPTO) Board of Appeals upheld the rejection of patent claims for the company's iTANK platform, a technology designed to enhance CAR-T cell therapies for treating solid tumors.

The Swedish clinical-stage cell and gene therapy company had appealed an examiner's initial decision to reject the patent claims for its commercially available iTANK platform. However, the Board of Appeals chose to maintain the examiner's rejection, dealing a blow to the company's intellectual property strategy in the crucial U.S. market.

Patent Attorney Disputes Decision

Henrik Sjölander, the company's Swedish patent attorney at Barker Brettell Sweden AB, expressed disagreement with the Board's conclusions. "The U.S. attorney and I do not agree with the conclusions of the Board of Appeals, which we believe are based on a hindsight assessment of the claimed invention," Sjölander stated. Despite the setback, he confirmed that the company has developed a strategy to continue pursuing patent protection for the iTANK platform in the United States.

International Patent Success Provides Optimism

The rejection in the United States contrasts sharply with the platform's patent success in other major markets. The iTANK platform has already secured patents in Europe and China, where respective patent offices deemed the invention patentable. This international recognition provides a foundation for CEO Jamal El-Mosleh's optimism that the USPTO will ultimately reach similar conclusions.

Revolutionary CAR-T Enhancement Technology

The iTANK technology platform addresses two major challenges facing CAR-T cell therapies in solid tumor treatment: the diverse set of tumor antigen targets and the hostile tumor microenvironment. The platform incorporates a transgene into CAR-T cells that encodes a neutrophil activating bacterial protein (NAP).

When secreted from CAR(NAP) T-cells, NAP enhances CAR-T cell function and activates a parallel bystander immune response against cancer through CD8+ killer T-cells. This mechanism is expected to create a broad attack against most antigen targets on cancer cells, potentially overcoming the limitations that have historically made solid tumors difficult to treat with CAR-T therapies.

Scientific Validation and Market Potential

The iTANK platform's scientific foundation was established through proof-of-concept data published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers," demonstrated the platform's potential to trigger potent immune responses against solid tumors.

Elicera's CAR-T cell therapies have shown potent effects against solid tumors, which constitute the majority of cancer cases and are recognized as particularly difficult to treat. The company addresses what it describes as a global multibillion-dollar market in cell therapy through non-exclusive licensing of the iTANK platform to pharmaceutical industry companies.

Broader Development Pipeline

Beyond the iTANK platform, Elicera Therapeutics (search)Search term maintains four internal development projects in immune therapy, each with potential for substantial value through exclusive out-licensing agreements. The company develops next-generation cancer treatments based on oncolytic viruses and CAR-T cell therapies, all enhanced with immune-activating properties through the iTANK platform.

The patent application remains under examination by the USPTO, indicating that the regulatory process continues despite the Board of Appeals' decision. The company's strategic approach to overcoming this setback will be crucial for securing intellectual property protection in the United States, one of the world's largest pharmaceutical markets.